Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 May 2018 Photo Naledi Posholi
Could wave power be an answer to SAs electricity crisis
Attending a recent guest lecture, were from the left: Prof Marian Tredoux UFS Department of Geology, Prof Stoffel Fourie fromWalter Sisulu University, and Thoriso Lekoetje a third-year UFS Geology student.

South Africa has a 2800-km long coastline with high wave energy potential that can generate electricity. Presenting a lecture at the UFS Department of Geology, Prof Stoffel Fourie discussed wave power as a possible solution to the country’s electricity needs. Prof Fourie is a geophysicist and the chairperson of research and development in the faculty of engineering at Walter Sisulu University.

Power at any time
Wave power is a renewable and sustainable resource. “It can provide continuous base load power because wave energy systems do not suffer from ‘time of day’ issues as other renewable energy options. This means that it can generate power at any time of the day,” said Prof Fourie. 
Discussed also was the wave power advantages and disadvantages. 

Wave energy advantages
• Wave energy is a reliable renewable energy resource;

• Reduces dependency on fossil fuels;

• Wave energy is predictable and consistent;

• Generates little or no pollution to the environment compared to other energy resources; and

• Presents no barriers or difficulty to migrating fish and aquatic animals.

Wave energy disadvantages
• Wave energy conversion devices are location dependent, thus limiting possible sites where they can be implemented;

• Offshore wave energy devices can be a threat to shipping as they are too small to detect by radar; and

• High capital investment required for start-up costs, construction and maintenance.

“Looking at both advantages and disadvantages, there is no doubt that South Africa can use this method to harvest energy. With the right investment and political buy-in, wave power could provide a continuous supply of energy and contribute to all South Africa’s electricity needs,” Prof Fourie said.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept